Related Experiment Videos
[Clinical studies of 9, 3"-diacetylmidecamycin (author's transl)]
Abstract:
1. We had a chance to administer the "MOM dry syrup' (MOM fine granules) to 22 patients: 6 patients with streptococcal infections and 16 patients with other respiratory tract infections. The clinical efficacy was good in 16 cases and its rate was 80%. 2. The causative organisms were isolated from 9 cases: 6 cases with S. pyogenes, 2 with S. pneumoniae and 1 case with B. pertussis. All of the clinical isolates were eradicated except for the S. pyogenes strains. 3. Any remarked side effects were not observed but only eosinophilia in 2 cases. 4. Because of no bitterness of the MOM dry syrup, all the children take it easily. 5. MOM was effective in all the cases of pertussis and Mycoplasma pneumoniae pneumonia. As for streptococcal and pneumococcal infections, it is necessary to administer MOM under the control of bacterial sensitivity.
Insights
MOM dry syrup demonstrated 80% clinical efficacy in respiratory infections, including pertussis and Mycoplasma pneumoniae pneumonia. While generally safe, bacterial sensitivity monitoring is advised for streptococcal and pneumococcal cases.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Microbiology
Context:
- Respiratory tract infections are common in children.
- Antibiotic resistance necessitates evaluating new therapeutic options.
- MOM dry syrup offers a palatable alternative for pediatric patients.
Purpose:
- To evaluate the clinical efficacy and safety of MOM dry syrup in pediatric patients with respiratory tract infections.
- To identify the spectrum of bacterial pathogens involved and assess their susceptibility to MOM.
- To determine the palatability and ease of administration of MOM dry syrup in children.
Summary:
- MOM dry syrup was administered to 22 pediatric patients with streptococcal or other respiratory tract infections, achieving 80% clinical efficacy.
- Causative organisms included Streptococcus pyogenes, Streptococcus pneumoniae, and Bordetella pertussis. Eradication was observed in most cases, except for S. pyogenes strains.
- No significant side effects were noted, apart from eosinophilia in two patients. The syrup's lack of bitterness facilitated easy administration in all children.
Impact:
- MOM dry syrup shows promise as an effective treatment for pertussis and Mycoplasma pneumoniae pneumonia.
- For streptococcal and pneumococcal infections, careful monitoring of bacterial sensitivity is recommended for optimal therapeutic outcomes.
- The palatable nature of MOM dry syrup may improve medication adherence in pediatric populations.